Clinical Efficacy of Different Acid Inhibitors in the Treatment of Hp Infection with Reflux Esophagitis
Objective To compare the clinical efficacy and safety of vonoprazan quadruple therapy and rabeprazole quadruple therapy in the treatment of Helicobacter pylori(Hp)infection with reflux esophagitis(RE).Methods The clinical data of 265 patients with Hp infection and RE treated in the author's hospital from January to October 2023 were retrospectively analyzed.According to the therapeutic regimen,the patients were divided into vonoprazan group(n=102)and rabeprazole group(n=163).The clinical baseline data of patients with Hp infection and RE between two groups were compared,the eradication rate of Hp after treatment was analyzed,the gastroesophageal reflux disease questionnaire(GerdQ)score was recorded,the clinical efficacy was compared,and the occurrence of adverse reactions were compared.Results There was no significant difference in clinical baseline data of patients with Hp infection and RE between two groups(P＞0.05).The eradication rate of Hp in vonoprazan group was significantly higher than that in rabeprazole group(P＜0.05);after 6 weeks of treatments,the GerdQ score of vonoprazan group was significantly lower than that of rabeprazole group,the total effective rate of vonoprazan group was significantly higher than that of rabeprazole group(all P＜0.05),and there was no significant difference in the incidence of adverse reactions of patients with Hp infection and RE between the two groups(P＞0.05).Conclusion Vonoprazan quadruple therapy can significantly improve the eradica-tion rate of Hp infection with RE and the clinical efficacy of RE,which is a safety and effective therapeutic regimen.
NETL
NSTL
万方数据
